These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9518683)

  • 1. Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline in mice: in vivo and in vitro studies.
    Kotake Y; Tasaki Y; Hirobe M; Ohta S
    Brain Res; 1998 Mar; 787(2):341-3. PubMed ID: 9518683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain.
    Yamakawa T; Kotake Y; Fujitani M; Shintani H; Makino Y; Ohta S
    Neurosci Lett; 1999 Nov; 276(1):68-70. PubMed ID: 10586977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF.
    Kotake Y; Tasaki Y; Makino Y; Ohta S; Hirobe M
    J Neurochem; 1995 Dec; 65(6):2633-8. PubMed ID: 7595560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of Parkinson's disease-causing mechanism and development of anti-Parkinson's disease drugs using endogenous substances in brain].
    Ohta S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Feb; 25(1):39-42. PubMed ID: 15796069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective Effect of the Endogenous Amine 1MeTIQ in an Animal Model of Parkinson's Disease.
    Wąsik A; Romańska I; Michaluk J; Zelek-Molik A; Nalepa I; Antkiewicz-Michaluk L
    Neurotox Res; 2016 Apr; 29(3):351-63. PubMed ID: 26303030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate.
    Kotake Y; Yoshida M; Ogawa M; Tasaki Y; Hirobe M; Ohta S
    Neurosci Lett; 1996 Oct; 217(1):69-71. PubMed ID: 8905742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tetrahydroisoquinoline derivatives as possible Parkinson's disease-inducing substances].
    Kotake Y
    Yakugaku Zasshi; 2002 Nov; 122(11):975-82. PubMed ID: 12440154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous parkinsonism-inducing toxin, strongly potentiates MAO-dependent dopamine oxidation and impairs dopamine release: ex vivo and in vivo neurochemical studies.
    Wasik A; Romańska I; Antkiewicz-Michaluk L
    Neurotox Res; 2009 Jan; 15(1):15-23. PubMed ID: 19384584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction.
    Yamakawa T; Ohta S
    Neurosci Lett; 1999 Jan; 259(3):157-60. PubMed ID: 10025582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosynthesis of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), a possible antiparkinsonism agent.
    Tasaki Y; Makino Y; Ohta S; Hirobe M
    Adv Neurol; 1993; 60():231-3. PubMed ID: 8420139
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the Effects of Acute and Chronic Administration of Tetrahydroisoquinoline Amines on the In Vivo Dopamine Release: A Microdialysis Study in the Rat Striatum.
    Wąsik A; Romańska I; Antkiewicz-Michaluk L
    Neurotox Res; 2016 Nov; 30(4):648-657. PubMed ID: 27568335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells.
    Shavali S; Carlson EC; Swinscoe JC; Ebadi M
    J Neurosci Res; 2004 May; 76(4):563-71. PubMed ID: 15114628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)Deprenyl (Selegiline): past, present and future.
    Knoll J
    Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of 1-methyl-1,2,3,4-tetrahydroisoquinoline-synthesizing enzyme from rat brain: a possible Parkinson's disease-preventing enzyme.
    Yamakawa T; Ohta S
    Biochem Biophys Res Commun; 1997 Jul; 236(3):676-81. PubMed ID: 9245712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities.
    Tasaki Y; Makino Y; Ohta S; Hirobe M
    J Neurochem; 1991 Dec; 57(6):1940-3. PubMed ID: 1940911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline.
    Kikuchi K; Nagatsu Y; Makino Y; Mashino T; Ohta S; Hirobe M
    Drug Metab Dispos; 1991; 19(1):257-62. PubMed ID: 1673411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinsonism-preventing activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo.
    Okuda K; Kotake Y; Ohta S
    Biol Pharm Bull; 2006 Jul; 29(7):1401-3. PubMed ID: 16819177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ), an endogenous neurotoxin, induces dopaminergic cell death through apoptosis.
    Shavali S; Ebadi M
    Neurotoxicology; 2003 Jun; 24(3):417-24. PubMed ID: 12782106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.